Related Experiment Video
Updated: May 14, 2026
14:32
Real-time Analyses of Retinol Transport by the Membrane Receptor of Plasma Retinol Binding Protein
Published on: January 28, 2013
α-Tocopherol binding to human serum albumin
Gabriella Fanali1, Mauro Fasano, Paolo Ascenzi
1Division of Biomedical Sciences, Department of Theoretical and Applied Sciences, Center of Neuroscience, University of Insubria, Busto Arsizio (VA), Italy. gabriella.fanali@uninsubria.it
Biofactors (Oxford, England)
|January 29, 2013
Summary
Human serum albumin (HSA) binds alpha-tocopherol (vitamin E), likely within its FA3-FA4 site. This interaction suggests HSA plays a role in distributing vitamin E throughout the body.
Area of Science:
- Biochemistry
- Pharmacology
- Molecular Biology
Background:
- Human serum albumin (HSA) is a key transporter of hydrophobic molecules in the bloodstream.
- Alpha-tocopherol, the primary form of vitamin E, is a hydrophobic antioxidant crucial for cellular health.
- Understanding the binding interactions of HSA with vitamin E is essential for elucidating its biological transport and function.
Purpose of the Study:
- To investigate the binding characteristics and location of alpha-tocopherol when interacting with human serum albumin.
- To explore the influence of other ligands on the binding of alpha-tocopherol to HSA.
- To determine the potential role of HSA in the cellular uptake and distribution of alpha-tocopherol.
Main Methods:
- Characterization of alpha-tocopherol binding to HSA using equilibrium dissociation constant (Kd0) measurements.
- Employing competitive and allosteric modulation assays with various endogenous and exogenous ligands.
- Utilizing full-length and truncated forms of HSA (Asp1-Glu382) to identify binding sites.
Main Results:
- Alpha-tocopherol binds to HSA with a Kd0 of (7.0 ± 3.0) × 10(-6) M at pH 7.2 and 25.0°C.
- Binding studies indicate that alpha-tocopherol preferentially occupies the FA3-FA4 site on HSA.
- Ligand competition and allosteric modulation experiments confirmed the specific binding site and interactions.
Conclusions:
- HSA exhibits a defined binding affinity and site specificity for alpha-tocopherol.
- The FA3-FA4 site is the primary accommodation site for alpha-tocopherol on HSA.
- HSA's known cellular interactions suggest a significant role in the systemic transport and tissue distribution of vitamin E.
Related Concept Videos
01:30Drug Binding to Blood Components
When drugs enter systemic circulation, they interact with various components of the blood, including proteins such as human serum albumin (HSA), α1-acid glycoprotein (AAG), lipoproteins, globulins, and red blood cells (RBCs).
HSA is the most abundant plasma protein and is vital in drug binding. It contains distinct drug-binding sites, with different drugs exhibiting affinity for specific sites. There are three main drug-binding domains for HSA: sites I, II, and III. These domains are further...
HSA is the most abundant plasma protein and is vital in drug binding. It contains distinct drug-binding sites, with different drugs exhibiting affinity for specific sites. There are three main drug-binding domains for HSA: sites I, II, and III. These domains are further...
01:29Drug Distribution: Plasma Protein Binding
Drugs predominantly attach to plasma proteins, with only a small percentage remaining unbound. The unbound portion can be calculated as one minus the bound fraction. Acidic drugs form large, inactive complexes by reversibly binding to plasma albumin, which prevents them from diffusing across biological barriers. These drug-protein complexes act as reservoirs for the drugs. As the concentration of unbound drugs decreases, these complexes quickly dissociate to release the free drug, maintaining...
01:20Factors Affecting Protein-Drug Binding: Protein-Related Factors
Drug binding to proteins is a key aspect of pharmacokinetics and can influence a drug's distribution, absorption, and elimination in the body. Several factors, including the drug's physiochemical properties, protein concentration, disease states, and the number of binding sites on the protein, influence this process.
The physicochemical properties of a drug play a significant role in its ability to bind to proteins. Lipophilic drugs, which dissolve in fats, oils, and lipids, can be bound by...
The physicochemical properties of a drug play a significant role in its ability to bind to proteins. Lipophilic drugs, which dissolve in fats, oils, and lipids, can be bound by...
01:18Factors Affecting Protein-Drug Binding: Drug-Related Factors
Drug binding to proteins is a complex phenomenon influenced by various drug-related factors, each playing a significant role in the interaction between drugs and proteins within the body.
One crucial factor in drug-protein binding is the drug's lipophilicity or its affinity for fat. More lipophilic drugs tend to have higher binding extents. For example, highly lipophilic drugs like cloxacillin exhibit substantial protein binding, with as much as 95% of the drug binding to proteins. In contrast,...
One crucial factor in drug-protein binding is the drug's lipophilicity or its affinity for fat. More lipophilic drugs tend to have higher binding extents. For example, highly lipophilic drugs like cloxacillin exhibit substantial protein binding, with as much as 95% of the drug binding to proteins. In contrast,...
01:09Hepatic Drug Clearance: Effect of Protein Binding
Hepatic clearance is influenced by protein binding based on the drug's extraction ratio. Drugs with high extraction ratios are considered flow-limited and remain unaffected by protein binding during hepatic clearance. On the other hand, drugs with low extraction ratios may be impacted by plasma protein binding, although the extent of this influence depends on the fraction of the drug bound.
For low-extraction-ratio drugs that are less than 80% protein-bound, minor changes in protein binding...
For low-extraction-ratio drugs that are less than 80% protein-bound, minor changes in protein binding...
01:29Factors Affecting Protein-Drug Binding: Patient-Related Factors
Protein-drug binding, a pivotal aspect of pharmacokinetics, is subject to considerable variability influenced by an array of patient-related factors. The intricate interplay of age, individual differences, and pathological conditions significantly impact the binding dynamics and subsequent pharmacological effects.
Age stands as a key determinant in protein-drug binding. Neonates, characterized by low albumin content, experience heightened concentrations of unbound drugs such as phenytoin and...
Age stands as a key determinant in protein-drug binding. Neonates, characterized by low albumin content, experience heightened concentrations of unbound drugs such as phenytoin and...